<SEC-DOCUMENT>0001628280-23-034134.txt : 20231010
<SEC-HEADER>0001628280-23-034134.hdr.sgml : 20231010
<ACCEPTANCE-DATETIME>20231010120445
ACCESSION NUMBER:		0001628280-23-034134
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231009
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20231010
DATE AS OF CHANGE:		20231010

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aquestive Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001398733
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				208623253
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38599
		FILM NUMBER:		231316851

	BUSINESS ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		908-941-1900

	MAIL ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MonoSol Rx, Inc.
		DATE OF NAME CHANGE:	20070507
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aqst-20231009.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:1fa28e96-b96b-491d-91c6-3916bb3e197c,g:75ad8582-61de-44a1-b819-820f2cf167e9,d:fd6cf61207684c8eb767af70b98e107e--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>aqst-20231009</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001398733</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="aqst-20231009.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-09</xbrli:startDate><xbrli:endDate>2023-10-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifd6cf61207684c8eb767af70b98e107e_1"></div><div style="min-height:38.16pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-right:-0.95pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.160%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington, DC 20549</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.289%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.289%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PURSUANT TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">October 9, 2023</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.289%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Aquestive Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(Exact name of Registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.289%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.160%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38599</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">82-3827296</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">30 Technology Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Warren</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">NJ</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">07059</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">(908)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">941-1900</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">________________________________________________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:552.00pt"><tr><td style="width:1.0pt"></td><td style="width:34.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:513.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.160%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name of each exchange on which<br/>registered</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">AQST</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9746;</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifd6cf61207684c8eb767af70b98e107e_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Other Events</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 9, 2023, Aquestive Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release providing a business update on its lead pipeline programs and base business results.  The business update includes 1) the receipt of feedback from the U.S. Food and Drug Administration (FDA) on the Company's proposed pivotal study protocol for Anaphylm&#8482; (epinephrine) Sublingual Film, including that the Company&#8217;s proposed endpoints, sample size, and statistical analysis are reasonable and reminding the Company that pharmacokinetics (PK) sustainability post-dosing (30 &#8211; 60 minutes) is an important factor and recommending that the Company use repeat-dose data to support PK sustainability; 2) reaffirmation of expected fourth quarter 2023 Anaphylm pivotal Phase 3 study start and expected first quarter 2024 topline data readout; 3) outline of expected remaining activities for the Anaphylm program prior to submission of the New Drug Application (NDA) for Anaphylm to the FDA; 4) indication that the FDA review of Libervant&#8482; (diazepam) Buccal Film NDA is on track with no current open questions from the FDA; and 5) anticipation of increasing 2023 revenue and decreasing non-GAAP adjusted EBITDA loss guidance in upcoming earnings release.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A copy of the Company&#8217;s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cautionary Note Regarding Forward-Looking Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain statements in this Current Report on Form 8-K include &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, the advancement and related timing of our product candidate Anaphylm through clinical development and approval by the FDA, including the filing of pivotal PK clinical trials and other supporting clinical studies for Anaphylm; regarding the Company&#8217;s ability to provide sufficient data in its NDA submission to address the FDA&#8217;s recent comments on the Company&#8217;s proposed pivotal PK study protocol and the FDA&#8217;s other concerns following the End-of-Phase 2 meeting with the FDA; regarding the FDA&#8217;s approval for U.S. market access and the related timing of the filing of the NDA for Libervant with the FDA; regarding the 2023 financial outlook of the Company and its financial and operating results and financial position</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and other statements that are not historical facts. These forward-looking statements are based on the Company&#8217;s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company&#8217;s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials for Anaphylm and Libervant; risk of the Company&#8217;s failure to generate sufficient data in its PK/PD comparability submission for FDA approval of Anaphylm or that subsequent studies will not match results seen in prior studies; risk of the Company&#8217;s failure to address the concerns of the FDA, including those identified in the End-of-Phase 2 meeting for Anaphylm, and the risk that the FDA may require additional clinical studies for Anaphylm and Libervant; risk of delays in or the failure to receive FDA approval of Anaphylm and Libervant, including for U.S. market access for Libervant; </span><span style="color:#293749;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">risk that a competing pediatric epilepsy product of Libervant will receive FDA approval prior to the Company&#8217;s receipt of FDA approval of the Libervant NDA for these epilepsy patients aged between 2 and 5 years; risk relating to the unpredictability of the FDA&#8217;s decisions regarding orphan drug exclusivity; risk of litigation brought by third parties relating to overcoming their orphan drug exclusivity of an FDA approved product should the FDA approve Libervant for U.S. market access for any age group of epilepsy patients; risk in obtaining market access for Libervant for other reasons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and there can be no assurance that the Company will be successful in obtaining any such approvals; risk of insufficient capital and cash resources, including insufficient access to available debt and equity financing and revenues from operations, to satisfy all of the Company&#8217;s short-term and longer term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to fund future clinical development activities for Anaphylm and Libervant; risk of the success of any competing products; uncertainties related to general economic, political, business, industry, regulatory, financial and market conditions and other unusual items; and other risks and uncertainties affecting the Company described in the &#8220;Risk Factors&#8221; section and in other sections included in its Annual Report on Form 10-K, in its Quarterly Reports on Form 10-Q, and in its Current Reports on Form 8-K filed with the Securities and Exchange Commission.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this Current Report on Form 8-K, whether as a result of new information, future events or otherwise, except as may be required by applicable law. Readers should not rely upon this information as current or accurate after its publication date.</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 9.01</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Financial Statements and Exhibits</span></div></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:80%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:80%;padding-left:19.84pt">Exhibits.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="aqstbusinessupdate.htm">99.1</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="aqstbusinessupdate.htm">Press Release, dated </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="aqstbusinessupdate.htm">October 9</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="aqstbusinessupdate.htm">, 2023, </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="aqstbusinessupdate.htm">provid</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="aqstbusinessupdate.htm">in</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="aqstbusinessupdate.htm">g</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="aqstbusinessupdate.htm"> </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="aqstbusinessupdate.htm">Aquestive</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="aqstbusinessupdate.htm"> Therapeutics Business Update</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifd6cf61207684c8eb767af70b98e107e_10"></div><hr style="page-break-after:always"/><div style="min-height:38.16pt;width:100%"><div><span><br/></span></div></div><div style="padding-right:-0.47pt;text-align:center"><span><br/></span></div><div style="padding-right:-0.47pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SIGNATURE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="padding-left:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.730%"><tr><td style="width:1.0%"></td><td style="width:33.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dated: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 9, 2023</span></div></td><td colspan="6" style="padding:2px 1pt 2px 101pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Aquestive Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 101pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ A. Ernest Toth, Jr</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name: A. Ernest Toth, Jr.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aqstbusinessupdate.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idf0df6ae7cf843aa993388c631a6a11f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Aquestive Therapeutics Provides Business Update</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:14.15pt">Receives positive feedback from FDA on pivotal study protocol for Anaphylm</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8482;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> (epinephrine) Sublingual Film</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:14.15pt">Reaffirms Q4 2023 Anaphylm pivotal phase 3 study start and Q1 2024 topline data readout</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:14.15pt">Outlines expected remaining activities for  Anaphylm program prior to NDA submission</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:14.15pt">Indicates FDA review of Libervant&#8482; (diazepam) Buccal Film on track with no open questions </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:14.15pt">Anticipates increasing 2023 revenue and decreasing non-GAAP adjusted EBITDA loss guidance in upcoming earnings release</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WARREN, N.J., October 9, 2023 -- Aquestive Therapeutics, Inc. (NASDAQ&#58;AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided a business update on its lead pipeline programs and base business results.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company recently received comments from the U.S. Food and Drug Administration (FDA) on its pivotal Phase 3 pharmacokinetic (PK) clinical study protocol for Anaphylm&#8482; (epinephrine) Sublingual Film. Anaphylm</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">is a polymer matrix-based epinephrine prodrug administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine. Anaphylm comes in a highly portable package with the durability to withstand many of the norms of daily life. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In its comments, the FDA indicated that the Company&#8217;s proposed endpoints, sample size, and statistical analysis are reasonable. As anticipated, the FDA also reminded the Company that PK sustainability post-dosing (30 &#8211; 60 minutes) is an important factor and recommended using repeat-dose data to support PK sustainability. The Company has incorporated the FDA&#8217;s feedback into its upcoming studies and remains on track to start the pivotal Phase 3 study in Q4 2023. Table 1 below provides a list of anticipated clinical and regulatory activities to be completed prior to the planned New Drug Application (NDA) submission for Anaphylm in the second half of 2024.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Anticipated Timing</font></td><td colspan="3" style="border-bottom:2pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Pivotal PK Studies</font></td><td colspan="3" style="border-bottom:2pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Supportive PK Studies</font></td><td colspan="3" style="border-bottom:2pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">FDA Meetings &#47; Actions</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.017%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Q4 2023 &#8211; Q1 2024</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Phase 3 PK Study</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Temperature&#47;pH PK Study</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Type C Meeting</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">2</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Repeat Dose PK Study</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Q2 2024 &#8211; Q3 2024</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Pediatric PK Study</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Self-administration PK Study</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:29pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Sublingual Angioedema PK Study</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Pre-Submission</font></td><td colspan="3" style="border-bottom:2pt solid #000000;border-left:0.5pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-left:0.5pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-left:0.5pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Pre-NDA Meeting</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Timeline does not include chemistry, manufacturing and controls (CMC), preclinical and human factors activities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Determination of whether a sublingual angioedema study is needed will occur in the Type C Meeting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As previously announced, the Company&#8217;s NDA for approval of Libervant for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i.e</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">., seizure clusters, acute repetitive seizures) in patients between two and five years of age was recently accepted for review by the FDA. Diastat&#174; (diazepam) Rectal Gel is the only approved treatment currently available to this patient population for this indication. Based on the latest information available to the Company, the review for this NDA remains on track and there are currently no outstanding information requests from the FDA.  The NDA for Libervant has a PDUFA assignment date of April 28, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the Company&#8217;s base business continues to generate strong results. Based on preliminary Q3 results and binding supply purchase orders, the Company anticipates increasing current full year guidance on revenue and decreasing full-year guidance on non-GAAP-adjusted EBITDA loss. Updated guidance will be provided during the Company&#8217;s third quarter earnings call in early November. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;We are pleased with the progress we have made in multiple areas of our business,&#8221; stated Daniel Barber, Chief Executive Officer of Aquestive. &#8220;Our base business remains on track to have double-digit growth in 2023, we are on track to bring Libervant to pediatric patients under the age of 6, if approved by the FDA for U.S. market access, and we remain on track to launch Anaphylm in 2025, if approved by the FDA. We believe these advancements are important steps forward for the Company and for the patients who may benefit from our products.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Anaphylm&#8482; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anaphylm is a polymer matrix-based epinephrine prodrug candidate product  The product is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a pocket, and is designed to withstand weather excursions such as exposure to rain and&#47;or sunlight. The tradename for AQST-109 &#8220;Anaphylm&#8221; has been conditionally approved by the FDA. Final approval of the Anaphylm proprietary name is conditioned on FDA approval of the product candidate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Libervant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8482;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Libervant is a buccally, or inside of the cheek, administered film formulation of diazepam, a benzodiazepine intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient&#8217;s usual seizure pattern. Aquestive developed Libervant as an alternative to the device-based products currently available for patients with refractory epilepsy, including a rectal gel and nasal spray products. The FDA has granted tentative approval for Libervant for the treatment of these epilepsy patients 12 years of age and older, with U.S. market access for Libervant for this age group of patients subject to the expiration of the existing orphan drug market exclusivity of a previously FDA approved drug scheduled to expire in January 2027. The NDA submitted for Libervant for epilepsy patients between two and five years of age is subject to FDA approval, including for U.S. market access, and has been given a PDUFA assignment date of April 28, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">About Aquestive</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Aquestive is a pharmaceutical company advancing medicines to solve patients&#8217; problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm&#174;, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. For more information, visit&#160;</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Aquestive.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;and follow us on LinkedIn.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Forward-Looking Statement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain statements in this press release include &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidate Anaphylm&#8482; (epinephrine) Sublingual Film through clinical development and approval by the FDA, including the filing of pivotal PK clinical trials and other supporting clinical studies for Anaphylm&#59; regarding the Company&#8217;s ability to provide sufficient data in its NDA submission to address the FDA&#8217;s recent comments on the Company&#8217;s proposed pivotal PK study protocol and the FDA&#8217;s other concerns following the End-of-Phase 2 meeting with the FDA&#59; regarding the Company&#8217;s ability to commercialize Anaphylm in 2025&#59; regarding the FDA&#8217;s approval and related timing of the filing of the NDA for Libervant with the FDA for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i.e</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">., seizure clusters, acute repetitive seizures) that are distinct from a patient&#8217;s usual seizure pattern in patients with epilepsy between two and five years of age&#59; regarding the approval for U.S. market access of Libervant for these epilepsy patients aged 12 years and older, and overcoming the orphan drug market exclusivity of a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">competing FDA approved nasal spray product extending to January 2027 for this age group of the patient population&#59; regarding the potential benefits Anaphylm and Libervant could bring to patients&#59; regarding the 2023 financial outlook of the Company and its growth and future financial and operating results and financial position&#59; and other statements that are not historical facts. These forward-looking statements are subject to the uncertain impact of the COVID-19 global pandemic on the Company&#8217;s business including with respect to its clinical trials including site initiation, enrollment and timing and adequacy of clinical trials&#59; on regulatory submissions and regulatory reviews and approval of Anaphylm&#59; pharmaceutical ingredient and other raw materials supply chain, manufacture, and distribution&#59; and ongoing availability of an appropriate labor force and skilled professionals.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">These forward-looking statements are based on the Company&#8217;s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company&#8217;s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials for Anaphylm, Libervant and our other product candidates&#59; risk of the Company&#8217;s failure to generate sufficient data in its PK&#47;PD comparability submission for FDA approval of Anaphylm&#59; risk of the Company&#8217;s failure to address the FDA&#8217;s comments on the Company&#8217;s pivotal PK study protocol and other concerns identified in the FDA End-of-Phase 2 meeting for Anaphylm, including the risk that the FDA may require additional clinical studies for approval of Anaphylm&#59; risk of delays in or the failure to receive FDA approval of Anaphylm&#59; risks that the FDA will not approve Libervant for U.S. market access by overcoming the seven year orphan drug market exclusivity of an FDA approved nasal spray product in effect until January 2027&#59; risk of delays in or the failure to receive FDA approval of the NDA for Libervant for these epilepsy patients between two and five years of age, including the risk that the FDA may require additional clinical studies for approval of Libervant for this age group, and there can be no assurance that the Company will be successful in obtaining any of the foregoing FDA approvals for Anaphylm and Libervant, including for U.S. market access for Libervant&#59; </font><font style="color:#293749;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">risk that a competing pediatric epilepsy product of Libervant will receive FDA approval prior to the Company&#8217;s receipt of FDA approval of the Libervant NDA for these epilepsy patients aged between 2 and 5 years&#59; risk relating to the unpredictability of the FDA&#8217;s decisions regarding orphan drug exclusivity&#59; risk of litigation brought by third parties relating to overcoming their orphan drug exclusivity of an FDA approved product should the FDA approve Libervant for U.S. market access for any age group of epilepsy patients&#59; risk in obtaining market access for Libervant for other reasons&#59; risks associated with the Company&#8217;s development work, including any delays or changes to the timing, cost and success of the Company&#8217;s product development activities&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">risk of the success of any competing products</font><font style="color:#293749;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks, and regulatory limitations)&#59; risk of the rate and degree of market acceptance of our product candidates, including Anaphylm and Libervant&#59; risk of insufficient capital and cash resources, including insufficient access to available debt and equity financing and revenues from operations, to satisfy all of the Company&#8217;s short-term and longer term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to fund future clinical development activities for Anaphylm, Libervant and our other product candidates&#59; risk that our manufacturing capabilities will be sufficient to support demand for existing and potential future licensed products in the U.S. and other countries&#59; risk of the success of any competing products&#59; risk of eroding market share for Suboxone&#174; and risk of a sunsetting product, which accounts for the substantial part of our current operating revenue&#59; risk of the size and growth of our product markets&#59; risks of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities&#59; risks associated with intellectual property rights and infringement claims relating to the Company's products&#59; risk of unexpected patent developments&#59; uncertainties related to general economic, political, business, industry, regulatory, financial and market conditions and other unusual items&#59; and other risks and uncertainties affecting the Company described in the &#8220;Risk Factors&#8221; section and in other sections included in the Company&#8217;s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PharmFilm&#174; and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Investor Inquiries&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ICR Westwicke </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stephanie Carrington<br></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">stephanie.carrington&#64;westwicke.com<br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">646-277-1282</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>aqst-20231009.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:1fa28e96-b96b-491d-91c6-3916bb3e197c,g:75ad8582-61de-44a1-b819-820f2cf167e9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:aqst="http://aquestive.com/20231009" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://aquestive.com/20231009">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aqst-20231009_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aqst-20231009_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://aquestive.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>aqst-20231009_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:1fa28e96-b96b-491d-91c6-3916bb3e197c,g:75ad8582-61de-44a1-b819-820f2cf167e9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_cbc49c3f-314d-406e-b09c-d366fc9b9460_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7520a206-cbbc-41ee-a091-99df10d73b43_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_78d0fd7a-b0b1-45b1-ab33-b1094e080bb8_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_edfc68cb-bac5-4c0d-9b68-e0db3e5b4c67_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b01f8b1c-7653-4ede-8b57-94b0319cbbfb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_de856287-ed2f-4ba7-ba0c-3cdc3734bed8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_669915ff-b6b7-4773-8a01-5872863d0f66_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_2132cc8f-a15b-4a81-b152-0db8bc1d7da9_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9e635216-8b60-4e21-882b-8dc14ceafdc3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7604a879-bb76-4b37-8686-e6709f45e76a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_9d5e862d-096a-4c41-8378-4ec3786e62cc_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_9f850c36-c995-4341-b858-c3c4f22f220a_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9cda4be6-c38a-42f7-a805-3ee0102d5fc8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_65cd8fcb-440c-4fbb-b7be-9890add8bb71_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c0ab99c1-3382-4702-a461-0f0d109639f0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2e0db18c-65e9-4268-a66f-9a47cb3ab895_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_18bcba91-5657-4540-b811-dc4473cadf1a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_313d5fb2-f092-42d6-963d-5ce0c5bcee95_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_77fa105d-44b4-45bd-9d72-b2cd570fcaf0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_47180a13-116a-4952-874a-f340253e8904_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4a31a5c3-97ff-4563-a4ae-856525429a68_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_516a4021-4099-4b6b-99b7-129dfbbbbb2e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ee9b36cd-a8d7-4049-9fa8-fcb37adba7f2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>aqst-20231009_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:1fa28e96-b96b-491d-91c6-3916bb3e197c,g:75ad8582-61de-44a1-b819-820f2cf167e9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://aquestive.com/role/Cover" xlink:type="simple" xlink:href="aqst-20231009.xsd#Cover"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_de589750-3bcc-4513-85dc-7e99594e4c59" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_DocumentType_de589750-3bcc-4513-85dc-7e99594e4c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_39a91a7d-ca2c-427b-ad52-1a8f8ed27f3e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_DocumentPeriodEndDate_39a91a7d-ca2c-427b-ad52-1a8f8ed27f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_32e8c1ec-cba7-4e0e-a2f5-d4ada6fee4c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_EntityRegistrantName_32e8c1ec-cba7-4e0e-a2f5-d4ada6fee4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c982b23d-6215-4f44-bca2-de814fe9880c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c982b23d-6215-4f44-bca2-de814fe9880c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2ffb793d-5df4-4155-bc74-8712ae3523b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_EntityFileNumber_2ffb793d-5df4-4155-bc74-8712ae3523b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a5ea6b6d-0a78-4746-8cf7-db125da1b6da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_EntityTaxIdentificationNumber_a5ea6b6d-0a78-4746-8cf7-db125da1b6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ef8b634f-cdf4-4af5-a70f-fc8de8ad3ae2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_EntityAddressAddressLine1_ef8b634f-cdf4-4af5-a70f-fc8de8ad3ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e5eaa4cd-09bd-4a8b-b726-61e067a69b2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_EntityAddressCityOrTown_e5eaa4cd-09bd-4a8b-b726-61e067a69b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1e740538-0aae-4ce9-97ed-943fe0a73075" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_EntityAddressStateOrProvince_1e740538-0aae-4ce9-97ed-943fe0a73075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f7584b5e-628b-4c5d-b33c-2d3b652163f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_EntityAddressPostalZipCode_f7584b5e-628b-4c5d-b33c-2d3b652163f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b8b8cf53-f218-4b46-a255-835418cfb9da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_CityAreaCode_b8b8cf53-f218-4b46-a255-835418cfb9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ec2651a6-9555-4915-b90d-78dde0e2e4e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_LocalPhoneNumber_ec2651a6-9555-4915-b90d-78dde0e2e4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_79228e11-7e60-48e9-a759-6aa1af1ee99c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_WrittenCommunications_79228e11-7e60-48e9-a759-6aa1af1ee99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_aebc5ef4-4c06-4bfa-a24e-58c7cf865c5c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_SolicitingMaterial_aebc5ef4-4c06-4bfa-a24e-58c7cf865c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_57598b7d-8a0c-4f70-9b0d-f4a0740dc406" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_PreCommencementTenderOffer_57598b7d-8a0c-4f70-9b0d-f4a0740dc406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9285c977-7be2-4d95-8ff1-70782422a77c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9285c977-7be2-4d95-8ff1-70782422a77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e50069d7-f032-4b93-87a2-e71ae8f50fe9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_Security12bTitle_e50069d7-f032-4b93-87a2-e71ae8f50fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d84ce743-09bb-487b-a842-9db1a477c204" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_TradingSymbol_d84ce743-09bb-487b-a842-9db1a477c204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1c3d33d0-9604-40fe-a670-dd5ca1c000b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_SecurityExchangeName_1c3d33d0-9604-40fe-a670-dd5ca1c000b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_35a5de99-8c0e-456b-9c03-d1705d03c28d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_EntityEmergingGrowthCompany_35a5de99-8c0e-456b-9c03-d1705d03c28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_5937b370-a91e-446a-8d06-9f3a257ee8e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_EntityExTransitionPeriod_5937b370-a91e-446a-8d06-9f3a257ee8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7229ae8b-c66d-48b6-b86a-91b1962c62ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_EntityCentralIndexKey_7229ae8b-c66d-48b6-b86a-91b1962c62ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a6cc290e-cfe4-49c8-8776-92d781243e0c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b245c9d-bf88-43b1-b4f0-16a1d58cb0f1" xlink:to="loc_dei_AmendmentFlag_a6cc290e-cfe4-49c8-8776-92d781243e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
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M5B+,*6TZ&EWN&5:!R(V64,\3A'TXK%12W4I^,8_:AC;74X7__2$S/;^1/&;
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MJ,8.(>"[:"]FWKQY@FZMO[\_7"=^SF>??9;VI&CZA A==+>$XC/%\)/)"_6
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MH1'?D:-!$$^<TALB+"DI(7PP.)"P">0E'H"GAG/.SX_;B(Z.9H\Z.CKR#['
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M.-YXXPTB UITV$_^C,3V]G8W-S?:2IN;FW.-O;^__Y-//DED0-4,"0G1',9
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140433107239904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  09,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aquestive Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3827296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">30 Technology Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">941-1900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AQST<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001398733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>aqst-20231009_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aqst-20231009.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001398733</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-10-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Aquestive Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38599</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">82-3827296</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">30 Technology Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">941-1900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">AQST</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-21">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M(M=#QW?>'CSQ56SL W<TR.B*S9CY,YLJ:+FE2L13)C27@BBV'#IC_^HZZ-B
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M<9>>*G8>PO PF&&[O043$>R"'I?+(_G#]1K)*LOW<8?^@>Q>ZQS(&@%QV4;
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ EF!*5ZK$(A8S 0  (@(
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "68$I799!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ EF!*5YE<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " "68$I7>O.+364$   <$0  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ EF!*5Y^@&_"Q @
MX@P   T              ( !J P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" "68$I7EXJ[',     3 @  "P              @ &$#P  7W)E;',O+G)E
M;'-02P$"% ,4    " "68$I7JL0B%C,!   B @  #P              @ %M
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ EF!*5R0>FZ*M    ^ $
M !H              ( !S1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ EF!*5V60>9(9 0  SP,  !,              ( !LA(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="aqst-20231009.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="aqst-20231009.htm">aqst-20231009.htm</File>
    <File>aqst-20231009.xsd</File>
    <File>aqst-20231009_lab.xml</File>
    <File>aqst-20231009_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "aqst-20231009.htm": {
   "nsprefix": "aqst",
   "nsuri": "http://aquestive.com/20231009",
   "dts": {
    "inline": {
     "local": [
      "aqst-20231009.htm"
     ]
    },
    "schema": {
     "local": [
      "aqst-20231009.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "aqst-20231009_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aqst-20231009_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://aquestive.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20231009.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20231009.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-23-034134-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-034134-xbrl.zip
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M1R(A.]EW1L'Y9C(A[!KS(4(]9OYN[Q[*\5QY],?:SZ\0'>F"GWZ;]'SXQ9K
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M7 ,;2L0@,:F>-6RLOFEKJI-S\BEM>ZXV0(+!)0<>P8P.6)Q4J(S*0I).<?*
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MU7'KQC!C$^++L\,E6$>CM;IBHY'9KAUQ7[Z&:8B-J;(_9&UDHO\1ZZ;;'W/
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M*>VKO-O1'84!_7&GN(_80SL42!,O$Y!J$ ^K+X?(NJ%H((H$!DDE/:F41:G
M5UV-P0BM7SZ7N<!%,_ ^,<$"ILH2Y7,#CRDB"OX*FD*C\D6)LTN4VL8':T(@
M"Y$"AV_- 6[@KLS87((* )T0G,N98D6 :X:%E5,=ZWR)DHV722W OE+Z CZ3
M&O2JX9=0 A9!X"/XVE<GEF]9?$KY&]#6T9_1WKL)F5)Y+;YHT<?[QPZ)#6$T
M<D :9D;3ZTXF&6 <01B0Y )B<V $$CN9RGCID.B@=M&6FA3I T1$55A:X; &
M0L;.H$>,?DS8A(&!^O .V H^H-.2F@!//@P-&>FG.]N"8!T?BQ?; A8IP,0_
M(Z9+49TC>P"F(W"T@=<06-!'A(BPROA9E2E)2_H "0U-D>&[JY\?B::6 TV$
M_H2Q\+!').VJPE^5>@#4&2)#Y2V@@D+'GX'"B,#5_B*"0%$<+MA5?*S:0 Q\
M/ @PD0R,Q53%9E':*A3)&.B"#-Y ?:TB^<NS(I: G&4S&('/3Q49XUCA*U48
M0N#$,DWA(GJ/K+11O@.OL=^CQJXCE9;B19AQ!0<T@&_/91PA<!BBCFY4X>V3
MW[>!MT@I(I,>@<=&[L Q1,I'PYW104_*$U4AKK#U:GQ3.N+52]9>_NVIL: A
MA[#M6&9.'94_'(?: =:71SJE+=!+?RI'N[T]VN;D<0[@Y&'Y97][1+>>Y^'J
MO0F\N;>S]O;V:+SVWI7+[HT.)K>P[,%H?WO_YI>%F^/-EGU."&8D QT=Z(OO
MMG:V.J3VQ)MD.?JV8 1+9O?W*8S9'NVMNX_LVG?;AT&P\*48]T>/768QV=WE
MUB=[_V@&9:& >!3 K>3#(_=!X8WK#_>/M@^E-7@GSMB$/*)M [2=L47'D.\^
M,$=5N:\4M>C&_5M!#(:YCV^>[.X?BY. $EPM_))&?$ZVZ]$$_HU,8*>^S!FY
MKK19L^"?)UW)(\E:*W<H-JLW.T(C\-^=T?Y^6WYPY2[#)#H,8W5W$1H)4%G7
M*4,97[;97#MMHK>OQ=+]JI9^S)0ACU?9RT>4O/I%)9F":+.PBG1M]L];P Z;
MJR^3NNM$C=7RUOJZQV2TCRJ]O.9AXHMWUQBR)M>YS)1X79J]OU+P.FE'H9^M
MJ3]?S!Z\6],O:)\H+R1.,2]T._KG*L1L(UJV[DB6-P;DT:1O:M(GW'E1F?2=
M1Y/N3;H*-=86@D>CWHA.51P-9;OX]<"L^@9Z8')X^P;CYO3B7]@T-6J5)^E,
M&Q6J1-X/PWRNZ;B)/,N=F8Y[T(Y6#<]6^[SN)+.WH>S_+>"XZ0#HH6@.Y*_W
M=;YN@P3=[=>Q]T:3+XAW)J.#C6IU-P+JP6;!H4ZX"R@TRHG4Y%@DCHM0B6"N
M$K3PRP$V(A18ERXL=8*FR,UI;H&CQ=/7_W[];" RJUJUVGD![_A:MFN4:_]$
M)]'#IMGD'FAVJD ^P?]BW\M$8C%7^5S9=E^+K*VMK\(#?97"9H*%CF-A@J"P
M99F[G2/X^OJ]3K _1%UH4[AX":A)39$&96]'MY,$E0[V L@,VQ, E<TVVJH3
M2 9%CBUZ$'C3;!8\I%,B3)[#[P-!_48F7V80/ZA,.X-]#O!49-7O!37_*?U'
M@2U_+!Y+\?0A]*5NO=(C=1\]7:-!A1'00(@]-_!8QKZ7G"=D_"/8.9-6[95B
MJO*%4L#+"T/Z)\)'ETI:PCAU6TE7=_K)(% 9%G.1F+Y7>KHL6V)&XE1+[!3Z
MYLEX?[?5,?U)!5C0_%'%*$[XO$EQ/>(4;*JIV,%W>.+-"ZEC*AQ15PJ\Y\$6
MF<FPHZ7L/:%[OM,)KHW$]]319EA$8VP)1O7L&T+A<F?EBI.9K?V^JI7?4U]X
MIWL'D86Z0U$75 TT-H 7.?6AH<YO?I78US6[(PEGU&U4BDXM+G/JM_MP^NN;
M$R'!4YREA!YN1XW$269U+"8'@W9KS5>C>-X"E<#30L3U*YMVPRW:59T6W-<T
M4REFS['@: UU?W$W;LT7H--B;$>0=HEI&_\ -_)JIARVAV'W86$#*E"04^A:
ML#1:KEH]YV63<E2 N4!AJGO)B0UZF]'QX>'*PV6+^K"O17WD1Q+#^A6R4%-5
M]S*'['OT81"8VX;B]T):4!EU9SM8ZQAU!%R _;\'\4R )V^^:;(Y\[KJ0ZR;
M@O5._W;]BIR"AP[*;N65M4 T_SNO$AP9:+OA%,AQ/I018.1(Q@NY=%M?_[#N
M_4@XC91L'__&&C2C<8JP;NZE[GH4[84"70A6*9$AS6(D(*H:NU,EB@[J0@/^
M6*D)!K3L^)@Z5F&]4YEJ,#K?2PM,/!"OYUI%XH=+!>813=W/4:0#X'[4J.5@
MPTAXT'[&=3M]_:M-G 1<:,"!5,-0SW0N9M8L8!< *Y9\![@#W&+SI2E)9:WM
MX5)6)4TKZUQW4Z,E!AA?#(2.:JM9FUXR'M1L#YQRKG*RU,YQ\^Y"><!;(,02
M7+EYJW$3P-U;]X61 $I-06TJGIX M/ $A^*6?]QAW8T+JBJC@;>%M&'E^M5Z
ML[Y6;78Q-P#\$KZ1J@BP2%8225N.;XP\:6^N,_...FC8DYZ"7[ RG_!P#7#-
M%Y\U,A"@XT-.BB<;^S?E+["8 \,;2XJ@$!YD14D=W\CC\-\D0XD!2'#>QJ&9
M@H@8_D^1!S/T5,U0"N'-4#L>& +.1A\ 0H(1V"SP6M&F 8NY!9@SLR!?S)$+
MIJWW7]NY>.[ZYAD#LL>MIF:REFFJN,'<); H22:#!AK (O1@S,%EP7DDB)
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M!.$^:C30D26[1[@<%T>#6.K$K7A!7@B_=6M(6*357T7"^G7:,I'^V7:FH2J
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M/V/^_U!+ 0(4 Q0    ( )9@2E=C#BY\P1<  *&+   1              "
M 0    !A<7-T+3(P,C,Q,# Y+FAT;5!+ 0(4 Q0    ( )9@2E>X+D2M; (
M &<'   1              "  ? 7  !A<7-T+3(P,C,Q,# Y+GAS9%!+ 0(4
M Q0    ( )9@2E<[/(J_I0H   %A   5              "  8L:  !A<7-T
M+3(P,C,Q,# Y7VQA8BYX;6Q02P$"% ,4    " "68$I7^G#F/-\&  #O,@
M%0              @ %C)0  87%S="TR,#(S,3 P.5]P<F4N>&UL4$L! A0#
M%     @ EF!*5^Z9G8,D&0  S7P  !8              ( !=2P  &%Q<W1B
G=7-I;F5S<W5P9&%T92YH=&U02P4&      4 !0!( 0  S44

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
